CHMP recommends Roche's Tecentriq for urothelial carcinoma and NSCLC

EMA's CHMP recommended approval of Tecentriq atezolizumab (MPDL3280A, RG7446) from Roche (SIX:ROG; OTCQX:RHHBY) to treat locally advanced or metastatic urothelial carcinoma after prior platinum-contai...